Other formats:
BibTeX
LaTeX
RIS
@article{1418465,
author = {Vydra, Jan and Šálek, Cyril and Schwarz, Jiří and Žák, Pavel and Novák, Jan and Petečuková, Veronika and Pecherková, Pavla and Mayer, Jiří and Cetkovský, Petr and Ráčil, Zdeněk},
article_location = {DALLAS},
article_number = {2},
doi = {http://dx.doi.org/10.1016/j.clml.2017.11.011},
keywords = {Acute myeloid leukemia; Chemotherapy; Hematopoietic stem cell transplantation},
language = {eng},
issn = {2152-2650},
journal = {CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
title = {Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission},
volume = {18},
year = {2018}
}
TY - JOUR
ID - 1418465
AU - Vydra, Jan - Šálek, Cyril - Schwarz, Jiří - Žák, Pavel - Novák, Jan - Petečuková, Veronika - Pecherková, Pavla - Mayer, Jiří - Cetkovský, Petr - Ráčil, Zdeněk
PY - 2018
TI - Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission
JF - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
VL - 18
IS - 2
SP - 106-113
EP - 106-113
PB - CIG MEDIA GROUP, LP
SN - 21522650
KW - Acute myeloid leukemia
KW - Chemotherapy
KW - Hematopoietic stem cell transplantation
N2 - Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR). We present analysis of course and outcome of postremission therapy in 310 patients with AML with intermediate risk cytogenetics. Background: We retrospectively analyzed data from 310 patients with acute myeloid leukemia with intermediate-risk cytogenetics in first complete remission (CR1) to evaluate the usage and efficacy of various types of postremission therapy. Patients and Methods: Cox regression with time-dependent covariates, landmark analysis, and competing risk models were used to estimate the outcomes and effects of treatment and patient- and disease-related risk factors. Results: The early relapse rate and early nonrelapse mortality (NRM) were 12.8% and 4.4%, respectively. In our study, 77.2% of patients completed postremission therapy: 44% received allogeneic hematopoietic cell transplantation (HCT), 20% completed treatment with high-dose cytarabine (HIDAC), and 13% completed treatment with intermediate- dose cytarabine. The 3-year overall survival rate was 67.5% for patients treated with HIDAC and 63.4% after HCT (P =.5876). The NRM and relapse rate at 3 years were 0% and 58.9% after HIDAC and 21.9% and 29.3% after HCT, respectively. HCT reduced the risk of relapse (hazard ratio, 0.6; 95% confidence interval, 0.36-0.98). Total body irradiation-based myeloablative conditioning increased NRM compared with busulfan-based conditioning (hazard ratio, 8.33; 95% confidence interval, 2.52-27.45). Conclusion: Most patients with acute myeloid leukemia with intermediate- risk cytogenetics received allogeneic HCT, which decreased the risk of relapse but increased NRM, leading to a similar overall survival for patients who received HCT and HIDAC. Our data support the use of allogeneic transplantation for patients in CR1 from a human leukocyte antigen-matched related or unrelated donor after a busulfan-based myeloablative conditioning regimen as a primary strategy of postremission therapy for eligible younger patients.
ER -
VYDRA, Jan, Cyril ŠÁLEK, Jiří SCHWARZ, Pavel ŽÁK, Jan NOVÁK, Veronika PETEČUKOVÁ, Pavla PECHERKOVÁ, Jiří MAYER, Petr CETKOVSKÝ and Zdeněk RÁČIL. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. \textit{CLINICAL LYMPHOMA MYELOMA \&{}amp; LEUKEMIA}. DALLAS: CIG MEDIA GROUP, LP, vol.~18, No~2, p.~106-113. ISSN~2152-2650. doi:10.1016/j.clml.2017.11.011. 2018.
|
